We are pleased to announce that we have officially welcomed our first participant into the PIPELINE RSV-International trial.
RSV (Respiratory Syncytial Virus) is a common cause of cold-like symptoms during the winter months. While it is often mild, it can be quite serious for infants. In fact, RSV is a leading cause of hospital stays for children under 12 months old, and in some cases, it can lead to severe illness and even death.
Currently, there are two established ways to help prevent RSV: a vaccine given during pregnancy or a protective antibody given directly to the infant. Both methods are effective on their own but the PIPELINE RSV trial hopes to determine if providing the medicine to both mother and baby offers a higher level of protection than using either alone.
Reaching this milestone is a credit to the hard work of our clinical team and, most importantly, the families who participate in this research. We are sincerely grateful to our first participant for helping us work toward a future with better RSV protection for all infants.
